Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $66.47 USD
Change Today -0.77 / -1.15%
Volume 479.6K
ICLR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

icon plc (ICLR) Snapshot

Open
$67.01
Previous Close
$67.24
Day High
$67.47
Day Low
$66.00
52 Week High
03/23/15 - $72.40
52 Week Low
05/30/14 - $41.16
Market Cap
4.1B
Average Volume 10 Days
419.2K
EPS TTM
$3.14
Shares Outstanding
61.6M
EX-Date
--
P/E TM
21.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for ICON PLC (ICLR)

icon plc (ICLR) Related Businessweek News

No Related Businessweek News Found

icon plc (ICLR) Details

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It develops, manages, and analyzes programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company also offers clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics, and laboratory services. Its clinical development services include investigator recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety monitoring, risk-based monitoring, clinical data management, interactive response technologies, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, health economics, market access and commercialization services, strategic analysis and data operations, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, and study protocol preparation. The company’s clinical development services also comprise regulatory consulting, product development planning, strategic consulting, pricing and market access consulting, strategic resourcing, electronic endpoint adjudication, sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, biomarker development, adaptive trial design and execution, medical device trials, and healthcare communication services. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.

11,200 Employees
Last Reported Date: 05/15/15
Founded in 1990

icon plc (ICLR) Top Compensated Officers

Chief Executive Officer, Director and Chairma...
Total Annual Compensation: $6.6M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: $1.8M
Chief Operating Officer
Total Annual Compensation: $3.0M
Compensation as of Fiscal Year 2014.

icon plc (ICLR) Key Developments

ICON Public Limited Company Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Full Year 2015

ICON Public Limited Company reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported income from operations of $66,673,000, income before provision for income taxes of $66,670,000, net income of $55,869,000 or $0.90 diluted per share on net revenue of $388,231,000 against income from operations of $42,998,000, income before provision for income taxes of $43,089,000, net income of $36,195,000 or $0.57 diluted per share on net revenue of $349,634,000 for the same period a year ago. Cash generated from operating activities was $61.1 million. Capital expenditure was $10.7 million. For the full year 2015, the company increased earnings guidance from a range of $3.45 to $3.60 to a range of $3.60 to $3.70 and decreased revenue guidance from a range of $1,610 million $1,675 million to a range of $1,600 million to $1,650 million.

ICON Seeks Acquisitions

ICON Public Limited Company (NasdaqGS:ICLR) is seeking acquisitions. Ciaran Murray, Chief Executive Officer of ICON said, “We then also look at other parts of the market, bio techs and mid tier and other opportunities to make more partnership developments, or do we look at more tactical places. We also then look at adjacencies. Is it time to look at things that we are not as strong in at the minute, and either grow them organically, or then accelerate the top line through acquisitions.”

Icon plc Launches Firecrest eConsent

ICON plc announced Firecrest eConsent, a next-generation electronic informed consent solution that incorporates key recommendations from the FDA’s recent draft guidance on informed consent. The e-Consent solution is a component of ICON’s new informatics hub designed to enhance the engagement of patient populations in the development process. One of the critical parts to improving this engagement is improving the informed consent process. Addressing the FDA’s recommendation for a more patient centric approach to presenting clinical trial information, ICON’s Firecrest eConsent employs videos and visual aids to assist in the explanation of complex scientific concepts and medical terms found in trial protocols. These educational techniques were developed based on research by Carnegie Mellon University, and have been systematically tested, to facilitate optimal patient comprehension and information retention. Firecrest eConsent enables patients to access materials via portals or through other online channels provided by the sponsor, giving patients more time to independently review and prepare questions for the physician before subsequently consenting to participate in the trial. Conforming with the FDA’s requirement for validating that e-signatures are written by the actual patient, Firecrest eConsent uses a new proprietary method to capture, confirm, encrypt, and store biometrics for each patient’s signature. Firecrest eConsent has also been designed to be compatible with sites’ existing IT infrastructure, enabling sites to adopt the Firecrest eConsent solution quickly and efficiently.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICLR:US $66.47 USD -0.77

ICLR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ergomed PLC 173.00 GBp 0.00
INC Research Holdings Inc $33.91 USD +0.26
PAREXEL International Corp $68.70 USD +0.68
PRA Health Sciences Inc $32.37 USD -0.01
WuXi PharmaTech Cayman Inc $43.50 USD -0.13
View Industry Companies
 

Industry Analysis

ICLR

Industry Average

Valuation ICLR Industry Range
Price/Earnings 21.7x
Price/Sales 2.6x
Price/Book 4.0x
Price/Cash Flow 16.3x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICON PLC, please visit www.iconplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.